Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chenodiol

FDA-approved product (tablet, oral), marketed as Chenix, Chenodiol, Ctexli.

Registered studies
30
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Chenodiol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cerebrotendinous xanthomatosis
  • Inborn errors of metabolism

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Bile acids and derivatives
FDA pharmacologic class
Bile Acid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA69.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

30registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Chenodiol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chenodiol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

    NCT01865812 · start 2013-12-03

    Registered record
    Registry ID
    NCT01865812
    Conditions
    Primary Biliary Cirrhosis
    Interventions
    Obeticholic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-12-03
    Completion
    2016-09-12
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Biliary Cirrhosis
    InterventionObeticholic Acid
    PhasePhase 2
    Registry statusCompleted

  • Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)

    NCT01933503 · start 2013-10

    Registered record
    Registry ID
    NCT01933503
    Conditions
    Healthy
    Interventions
    OCA 5 mg; OCA 10 mg; OCA 25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10
    Completion
    2013-11
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOCA 5 mg; OCA 10 mg; OCA 25 mg
    PhasePhase 1
    Registry statusCompleted

  • Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)

    NCT01914562 · start 2013-08

    Registered record
    Registry ID
    NCT01914562
    Conditions
    Healthy
    Interventions
    OCA 10 mg; OCA 25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-08
    Completion
    2013-11
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOCA 10 mg; OCA 25 mg
    PhasePhase 1
    Registry statusCompleted

  • Hepatic Impairment Trial of Obeticholic Acid

    NCT01904539 · start 2013-06

    Registered record
    Registry ID
    NCT01904539
    Conditions
    Hepatic Impairment
    Interventions
    obeticholic acid 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06
    Completion
    2013-10
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    Interventionobeticholic acid 10 mg
    PhasePhase 1
    Registry statusCompleted

  • Effect of Bile Acids on GLP-1 Secretion

    NCT01666223 · start 2012-11

    Registered record
    Registry ID
    NCT01666223
    Conditions
    Type 2 Diabetes; Obesity
    Interventions
    Colesevelam; Chenodeoxycholic Acid; saline; Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-11
    Completion
    2013-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes; Obesity
    InterventionColesevelam; Chenodeoxycholic Acid; saline; Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg
    PhaseNot applicable
    Registry statusCompleted

  • Obeticholic Acid in Bile Acid Diarrhoea

    NCT01585025 · start 2012-04

    Registered record
    Registry ID
    NCT01585025
    Conditions
    Primary Bile Acid Malabsorption; Secondary Bile Acid Malabsorption; Chronic Diarrhoea
    Interventions
    Obeticholic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-04
    Completion
    2014-02
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Bile Acid Malabsorption; Secondary Bile Acid Malabsorption; Chronic Diarrhoea
    InterventionObeticholic acid
    PhasePhase 2
    Registry statusCompleted

  • Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

    NCT01473524 · start 2012-01

    Registered record
    Registry ID
    NCT01473524
    Conditions
    Primary Biliary Cirrhosis
    Interventions
    Obeticholic Acid (OCA); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2018-12-17
    Enrolment
    217

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Biliary Cirrhosis
    InterventionObeticholic Acid (OCA); Placebo
    PhasePhase 3
    Registry statusCompleted

  • Effect of Bile Acids on the Secretion of Satiation Peptides in Humans

    NCT01674946 · start 2011-09

    Registered record
    Registry ID
    NCT01674946
    Conditions
    Echolocation
    Interventions
    saline; bile acid (CDCA, chenodeoxycholic acid); oleanolic acid; oleic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-09
    Completion
    2012-05
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEcholocation
    Interventionsaline; bile acid (CDCA, chenodeoxycholic acid); oleanolic acid; oleic acid
    PhasePhase 1
    Registry statusCompleted

  • Cheno Effect on Transit in Health and IBS-C

    NCT00912301 · start 2009-04

    Registered record
    Registry ID
    NCT00912301
    Conditions
    Constipation-predominant Irritable Bowel Syndrome
    Interventions
    Sodium chenodeoxycholate (NaCDC); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-04
    Completion
    2009-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation-predominant Irritable Bowel Syndrome
    InterventionSodium chenodeoxycholate (NaCDC); Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

    NCT00570765 · start 2008-01-17

    Registered record
    Registry ID
    NCT00570765
    Conditions
    Liver Cirrhosis, Biliary
    Interventions
    Placebo; Obeticholic Acid (OCA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-01-17
    Completion
    2017-09-25
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis, Biliary
    InterventionPlacebo; Obeticholic Acid (OCA)
    PhasePhase 2
    Registry statusCompleted

  • Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

    NCT00550862 · start 2007-10

    Registered record
    Registry ID
    NCT00550862
    Conditions
    Liver Cirrhosis, Biliary
    Interventions
    INT-747; Ursodeoxycholic Acid (URSO); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-10
    Completion
    2010-12
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis, Biliary
    InterventionINT-747; Ursodeoxycholic Acid (URSO); Placebo
    PhasePhase 2
    Registry statusTerminated

  • Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism

    NCT00465751 · start 2004-10

    Registered record
    Registry ID
    NCT00465751
    Conditions
    Metabolic Syndrome; Familial Hypertriglyceridemia; Familial Combined Hyperlipidemia
    Interventions
    chenodeoxycholic acid; placebo capsules
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2004-10
    Completion
    Not recorded
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Syndrome; Familial Hypertriglyceridemia; Familial Combined Hyperlipidemia
    Interventionchenodeoxycholic acid; placebo capsules
    PhaseEarly phase 1
    Registry statusCompleted

  • Cholestanol in Humans

    NCT00018694 · start 1999-10

    Registered record
    Registry ID
    NCT00018694
    Conditions
    Cerebrotendinous Xanthomatosis
    Interventions
    Chenodeoxycholic Acid
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    1999-10
    Completion
    2009-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebrotendinous Xanthomatosis
    InterventionChenodeoxycholic Acid
    PhaseNot applicable
    Registry statusWithdrawn

  • Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis

    NCT00004346 · start 1996-01

    Registered record
    Registry ID
    NCT00004346
    Conditions
    Cerebrotendinous Xanthomatosis
    Interventions
    chenodeoxycholic acid; lovastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    1996-01
    Completion
    Not recorded
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebrotendinous Xanthomatosis
    Interventionchenodeoxycholic acid; lovastatin
    PhasePhase 2
    Registry statusUnknown

  • Study of Bile Acids in Patients With Peroxisomal Disorders

    NCT00004442

    Registered record
    Registry ID
    NCT00004442
    Conditions
    Infantile Refsum's Disease; Zellweger Syndrome; Bifunctional Enzyme Deficiency; Adrenoleukodystrophy
    Interventions
    chenodeoxycholic acid; cholic acid; ursodiol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    Not recorded
    Completion
    1999-04
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfantile Refsum's Disease; Zellweger Syndrome; Bifunctional Enzyme Deficiency; Adrenoleukodystrophy
    Interventionchenodeoxycholic acid; cholic acid; ursodiol
    PhaseNot applicable
    Registry statusTerminated